Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series
Open Access
- 26 March 2026
- journal article
- case report
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (4) , 206
Abstract
Bispecific antibodies targeting B-cell maturation antigen, BCMA (teclistamab) or G protein–coupled receptor, class C, group 5 member D, GPRC5D (talquetamab) are effective treatments for relapsed or refractory multiple myeloma. Their main early toxicity is cytokine release syndrome (CRS), usually transient and limited to initial cycles. We report five patients with relapsed or refractory multiple myeloma who received bispecific antibodies (n = 1 teclistamab; n = 4 talquetamab) who developed a pattern of recurrent, cyclic CRS beyond the initial step-up phase. All patients achieved at least a partial hematologic response, with complete or stringent complete remission in most cases. Recurrent febrile episodes occurred at regular intervals after drug administration, despite repeatedly negative infectious workups. CRS episodes were generally grade 1–2 and resolved with tocilizumab, with or without corticosteroids. In one patient treated with teclistamab, recurrent CRS contributed to treatment discontinuation due to renal complications. Attenuation of CRS severity over time was observed in some patients, allowing treatment continuation with tailored premedication strategies. This case series describes an unusual pattern of recurrent CRS occurring during bispecific antibody therapy for multiple myeloma. Recognition of this phenomenon is essential to avoid misdiagnosis as infection and unnecessary antimicrobial use. Systematic reporting of such real-world adverse events may help refine supportive care strategies.Keywords
Funding Information
- Università degli Studi di Napoli Federico II
This publication has 13 references indexed in Scilit:
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 studyThe Lancet Haematology, 2025
- T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of TreatmentBlood Cancer Discovery, 2024
- CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNature Communications, 2024
- International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaThe Lancet Oncology, 2024
- T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated KillingCancer Immunology Research, 2023
- Early and Late Toxicities of Chimeric Antigen Receptor T-CellsHematology/Oncology Clinics of North America, 2023
- Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myelomaCancer, 2023
- The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsCancer Cell, 2023
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studyThe Lancet, 2021
- Mechanisms underlying T cell ageingNature Reviews Immunology, 2019